Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 688.00 | |
5 mg | 35 days | $ 1,980.00 |
Description | Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface. |
Targets&IC50 | PPARγ LBD:(ki)1.2 μM, PPARγ LBD Leriglitazone: 680 nM(EC) |
Synonyms | Hydroxypioglitazone |
Molecular Weight | 372.44 |
Formula | C19H20N2O4S |
CAS No. | 146062-44-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Leriglitazone 146062-44-4 Others Hydroxypioglitazone inhibitor inhibit